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Conditioned medium from human monocytes contains a partially characterized hepatocyte-stimulating fac- 
tor that simultaneously elevates the mRNA levels of the acute-phase protein /3-fibrinogen and decreases al- 
bumin mRNA in rat hepatoma cells. We demonstrate that recombinant human B-cell stimulatory factor 
2, which is identical to interferon-/?,?/26 kDa protein and interleukin-HPl, exhibits the same activity as hepa- 
tocyte-stimulating factor. Furthermore, a specific antibody against B-cell stimulatory factor 2 was able to 
inhibit hepatocyte-stimulating factor in conditioned medium from human monocytes. Our data show that 
hepatocyte-stimulating factor and B-cell stimulatory factor 2 are functionally and immunologically related 
proteins. 
Acute-phase protein; Albumin; BSF-2; /?-Fibrinogen; Hepatocyte-stimulating factor; Interferon+0 
1. INTRODUCTION 
In many species disturbances of the physiologi- 
cal homeostasis lead to a complex series of local 
and systemic reactions, designated as the acute- 
phase reponse [l]. The systemic reaction is charac- 
terized by drastic changes in the levels of various 
plasma proteins, the so called acute-phase proteins 
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[2]. The major site of acute-phase protein synthesis 
is the liver. The igcreases in plasma levels of acute- 
phase proteins are preceded by increases in hepatic 
mRNA levels ([3,4], review [ 11). These changes are 
generated by mediators secreted by mononuclear 
phagocytes [5-81. With respect to acute-phase pro- 
tein regulation HSF [9-121, interleukin-1 [13-161 
and tumor necrosis factor a/cachectin [15,17] are 
the most thoroughly investigated of these mono- 
kines. Recently, the mediator responsible for in- 
duction of al-macroglobulin was discriminated 
from interleukin-1 and tumor necrosis factor cy by 
ourselves [18,19] and others [20-221. BSF-2 has 
been studied as a factor involved in the final dif- 
ferentiation of activated B cells into antibody- 
secreting cells [23]. The cDNA for BSF-2 was 
cloned and the results indicate that BSF-2 is iden- 
18 
Published by Elsevrer Scrence Publrshers B. V. (Blomedrcal Divisron) 
00145793/87/$3.50 0 1987 Federation of European Biochemical Societies 
Volume 221, number 1 FEBS 
to IFN-,&2, 26 kDa protein and interleukin 
HPl. Here, we describe that recombinant human 
BSF-2 acts as an acute-phase mediator on rat 
hepatoma cells. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Deoxycytidine 5’-[ol-32P]triphosphate (110 
TBq/mmol) was purchased from Amersham 
Buchler (Braunschweig). FCS (lot 85F-0541) and 
RPM1 1640 medium were from Sigma (Munich). 
Purified IFN-LY (3 x lo6 IU/ml; ch-B.: 11205008) 
and IFN-,& (2 x 10’ IU/mg protein), rhIFN$l 
(1.5 x 10’ IU/mg protein; ch-B.: 221.TlOOl) and 
rhIFN-y (1.5 x 10’ IU/mg protein; ch-B.: 
321.01003) were kindly supplied by Dr Obert (Bio- 
feron, Laupheim, FRG). BSF-2 (5 x lo6 U/mg 
protein) was prepared as described in [24]. Poly- 
clonal anti-BSF-2 (rabbit IgCi fraction, 1 mg/ml) 
inhibited 5 U of BSF-2 activity per ml at a dilution 
of 1:200. Albumin cDNA was supplied by Dr A. 
Alonso (DKFZ, Heidelberg) and P-fibrinogen 
cDNA by Dr A. Mitchell (Parkville, Australia). Dr 
F. Wiebel (GSF, Munich) provided the Fao-9 cells. 
2.2. Hepatoma cell culture 
Fao-9 cells were grown in RPM1 1640 medium 
containing 5% FCS, 100 mg/l streptomycin and 
65 mg/l penicillin and passaged once per week by 
trypsinization. For most experiments the cells were 
plated on a 24-well dish (Falcon, no. 3047) 2 days 
earlier. About 5 x lo5 cells per well were used for 
experiments. 
2.3. Cytoblot and mRNA hybridization 
Cells (5 x lo5 per well) were lysed in 10 mM 
Tris-HCl buffer (pH 7.0) containing 1 mM EDTA 
and 0.5% Nonidet P40, nuclei removed by cen- 
trifugation, cytoplasmic RNA denatured in the 
presence of formaldehyde essentially as in [25] and 
RNA blotted to a Gene Screen membrane (NEN) 
using a Manifold dot-blot apparatus (Schleicher 
and Schull). After baking the filters at 80°C for 
2 h and prehybridization for 6 h, the filters were 
hybridized to 32P-labeled cDNA probes [26]. The 
cDNAs were radiolabeled using the random primer 
technique in [27]. Specificity of hybridization was 
controlled by Northern blot analysis (not shown). 
2.4. Conditioned media from human monocytes 
and macrophages 
These were prepared as described in [18,19]. 
3. RESULTS AND DISCUSSION 
A well-differentiated rat hepatoma cell line 
(Fao-9) was used for studying alterations in p- 
fibrinogen and albumin mRNA levels as an in vitro 
system to measure the influence of mediators on 
acute-phase protein synthesis. Human purified 
IFN-LU and purified IFN-,0, rhIFN$l and rhIFN-y 
were added to Fao-9 cells in increasing amounts. 
As shown in fig. 1 only purified IFN-fl elevated fl- 
fibrinogen mRNA (A) and simultaneously lowered 
albumin mRNA levels (B). All other IFNs used - 
including rhIFN-/31 - had no effect. Conditioned 
media from human monocytes (cm-mo) and 
human macrophages (cm-M4) served as positive 
controls. Since very high concentrations of 
purified huIFN-fl were needed (50% increase in p- 
hu IFN-a 
hu IFN-B 
ret hu IFN - R, 
ret hu IFN-y 
B hu IFN - a 
huIFN-6 
0 
cm-m0 ret hu IFN - 8, 
cm-M0 ret hu IFN- y 
Fig.1. Induction of rat P-fibrinogen mRNA by human 
interferon-p. Fao-9 cells (5 x lo5 cells/well) were in- 
cubated with purified human interferon-a (hulFN-cu), 
purified human interferon+’ (huIFN@), recombinant 
human interferon-p1 (ret huIFN$l) and recombinant 
human interferon-y (ret hulFN-y) at the indicated con- 
centrations or with conditioned media from human 
monocytes (cm-mo) or macrophages (cm-M@) in the 
presence of lo- M dexamethasone for 12 h. The dif- 
ferent IFN concentrations were obtained by dilution in 
RPM1 1640 medium containing 5% FCS and 10m6 M 
dexamethasone shortly before addition to the cells. The 
cells were lysed, the cytoplasmic RNA extract blotted to 
a Gene Screen membrane and hybridized with “P- 
labeled B-fibrinogen cDNA (A) or albumin cDNA (B). 
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fibrinogen mRNA at 700 III/ml), and huIFN-PI 
had no effect, we concluded that a protein similar 
to human IFN-Pl, but still different from it, may 
be an acute-phase mediator. Recently, Gauldie 
reported that BSF-2 was able to act as an acute- 
phase mediator in HepG2 cells, Hep3B2 cells and 
rat hepatocyte primary cultures (personal com- 
munication, Cold Spring Harbor Symposium on 
II- 
0 lo* lo“ 1 10 lo* lo3 
BSF - 2 ( units/ml ) 
Fig.2. Regulation of P-fibrinogen and albumin mRNA 
levels by recombinant human B cell stimulatory factor 2 
(BSF-2). Fao-9 cells (5 x lo5 cells/well) were incubated 
with ret huBSF-2 at the indicated concentrations (A ,o) 
or with conditioned media from human monocytes 
(A,O) in the presence of 10e6 M dexamethasone for 
12 h. The dilution of ret huBSF-2 and hybridization of 
mRNA with “P-labeled P-fibrinogen cDNA (A,A) or 
albumin cDNA (o,o) were carried out as described in 
the legend to fig.1. For quantification the dots on the 
Gene Screen membrane were counted in a liquid scin- 
tillation counter. 
Regulation of Liver Gene Expression, 1987). From 
data obtained in several laboratories it became evi- 
dent that BSF-2 is identical to interferon-P2, the 
26 kDa protein [28-321 and the hybridoma/plas- 
mocytoma growth factor (interleukin-HPl) [33]. 
Therefore, we added rhBSF-2 to Fao-9 cultures. 
rhBSF-2 induced a 5.1-fold increase in ,&- 
fibrinogen mRNA levels (fig.2, filled triangles). At 
the same time albumin mRNA decreased 3.9-fold 
(closed circles). Only 4 U/ml of BSF-2 led to a 
half-maximal induction of P-fibrinogen mRNA. 
Assuming an M, of 21000 for BSF-2, this half- 
maximal induction is obtained at an rhBSF-2 con- 
pre - immunC serum 
IIP- 
10 40 160 0 
Titer of cm - mo 
Fig.3. Inhibition of hepatocyte-stimulating factor in 
conditioned medium from human monocytes by anti- 
BSF-2. 3 vols conditioned medium from human mono- 
cytes were pre-incubated with I vol. anti-BSF-2 (0) or 
pre-immune serum (m) at 25°C for 30 min. This 
pretreated conditioned medium was added to the culture 
medium of Fao-9 cells at the indicated dilutions. /3- 
Fibrinogen mRNA induction was measured as described 
in section 2. 
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centration of about 40 pM. Interestingly, pure 
rhBSF-2 was a more effective stimulant of ,8- 
fibrinogen mRNA synthesis than conditioned 
medium from human monocytes (open triangles). 
After having demonstrated that BSF-2 
stimulates P-fibrinogen mRNA synthesis, we fur- 
ther investigated the relationship between the T- 
cell derived BSF-2 and the monocyte-derived HSF. 
Therefore, we pre-incubated conditioned medium 
with anti-BSF-2 or with pre-immune serum. Fig.3 
shows that anti-BSF-2 neutralized about 70% of 
the hepatocyte-stimulating activity in conditioned 
medium from human monocytes (filled circles), 
whereas the pre-immune serum (filled squares) had 
no effect. The activity remaining after the addition 
of anti-BSF-2 could either be due to an incomplete 
neutralizing capacity of the antibody or to the 
presence of other acute-phase mediators in condi- 
tioned medium of monocytes. HSF in conditioned 
medium from human macrophages derived from 
monocytes by in vitro maturation, however, was 
totally blocked by anti-BSF-2 (not shown). 
Our data have shown a strong functional and 
immunological relationship between BSF-2/IFN- 
,82 and HSF. Experiments are underway to prove 
finally a possible identity by sequence data. Since 
the interferon activity of IFN-,82/BSF-2 is present- 
ly questioned [32], the stimulation of acute-phase 
protein synthesis in hepatocytes may be one of the 
major functions of IFN-,&2/BSF-2. 
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